Biktarvy in Treatment-Naïve Late Presenters With HIV-1 Infection

The Efficacy and Safety of Biktarvy in Treatment-Naïve Late Presenters With HIV-1 Infection

The efficacy and safety of Biktarvy in Treatment-Naïve Late Presenters with HIV-1 Infection

Study Overview

• Status: Completed
• Conditions: HIV-1-infection
• Intervention / Treatment: Drug: B/F/TAF; Drug: TDF/3TC/EFV

Detailed Description

HIV epidemic is still severe in China, the estimated number if PLWH in HIV is around 1.25 million all of China with an increasing trend of new cases. Late presenters with low CD4 T cells and/or with hight viral load should be paid more attention for better treatment and care. As a new combined antiretroviral regimen of integrase inhibitor, B/F/TAF was recently approved in US and European and also in China which needs more real world data in China. Non-inferiority or advantage of B/F/TAF comparing with the first line TDF/3TC/EFV for later presenters in China needs to be explored.

• Study Type: Interventional
• Enrollment (Actual): 202
• Phase: Phase 4

Contacts and Locations

Study Locations

• China
  • Tianjin, China, 300192
    • Tianjin Second People's Hospital
  • Guangxi
    • Liuzhou, Guangxi, China, 545005
      • The Guangxi Zhuang Autonomous Region Longtan Hospital
  • Guansu
    • Lanzhou, Guansu, China
      • Lanzhou Feike Hospital
  • Jiangsu
    • Najing, Jiangsu, China, 210003
      • The Second Hospital of Nanjing
  • Liaoning
    • Dalian, Liaoning, China
      • China Liaoning Dalian Public Health Clinical Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1.Ability to understand and sign a written informed consent form 2.18 years old or older 3.Confirmed HIV-antibody positive through Western Blot testing without any previous ART 4.CD4 < 200/mm3, VL >1000 copies/ml 5.Estimated glomerular filtration rate (GFR) ≥ 50 mL/min (calculated by CKD-EPI) 6.Clinical status relatively stable 7.Females of childbearing potential must agree to utilize highly effective contraception methods or be non-heterosexually from screening throughout the duration of study treatment and for 30 days following the last dose of study drug.

Exclusion Criteria:

1. A new AIDS-defining condition diagnosed within the 30 days prior to screening
2. Participants experiencing severe organ lesion.
3. Positive serum pregnancy test or planned to be pregnant.
4. Females who are breastfeeding
5. With carcinoma
6. Concomitant medication of immunosuppression or chemoradiotherapy
7. Participation in any other interventional clinical trial
8. Screening stage find: Hb < 9g/dL, WBC < 3000/ul. neutrophilic granulocyte< 1500/ul, PLT< 75000/ul. Scr > 1.5 ULN,Hepatic transaminases (AST and ALT) and ALP > 3 × ULN,total bilirubin ≤ 2 x ULN.
9. Any other clinical condition or prior therapy that, in the opinion of the Investigator, would make the subject unsuitable for the study or unable to comply with dosing requirements

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: B/F/TAF; 50mg/600mg/300mg	Drug: B/F/TAF; randomized, multicentered, open-lable RCT, one arm with B/F/TAF and one arm with TDF/3TC/EFV; Other Names: Biktarvy
Active Comparator: TDF/3TC/EFV; 300mg/300mg/400mg	Drug: TDF/3TC/EFV; TDF/3TC/EFV; Other Names: Tenofovir /Ravmidine /Efavirenz

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Proportion of participants with HIV-1 RNA < 50 copies/mL at Weeks 12	Proportion of participants with HIV-1 RNA < 50 copies/mL at Weeks 12	Weeks 12

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Proportion of participants with HIV-1 RNA < 50 copies/mL at Weeks 4,24,48	Proportion of participants with HIV-1 RNA < 50 copies/mL at Weeks 4,24,48	Weeks 4,24,48
The Change in CD4 T cell count from baseline at Weeks 12,24,48	The Change in CD4 T cell count from baseline at Weeks 12,24,48	Weeks 12,24,48
Change in CD4/CD8 ratio from baseline at Weeks 12,24,48	Change in CD4/CD8 ratio from baseline at Weeks 12,24,48	Weeks 12,24,48

Collaborators and Investigators

• Sponsor: Peking Union Medical College Hospital
• Collaborators: Gilead Sciences
• Investigators: Principal Investigator: Wei Lyu, Department of Infectious Diseases, PekingUMCH

Study record dates

Study Major Dates

• Study Start (Actual): July 14, 2021
• Primary Completion (Actual): December 13, 2022
• Study Completion (Actual): June 6, 2025

Study Registration Dates

• First Submitted: March 3, 2020
• First Submitted That Met QC Criteria: March 4, 2020
• First Posted (Actual): March 5, 2020

Study Record Updates

• Last Update Posted (Actual): June 5, 2026
• Last Update Submitted That Met QC Criteria: June 2, 2026
• Last Verified: June 1, 2026

More Information

Terms related to this study

• Keywords: HIV-1 infection; Biktarvy
• Additional Relevant MeSH Terms: Pathologic Processes; RNA Virus Infections; Virus Diseases; Blood-Borne Infections; Sexually Transmitted Diseases, Viral; Sexually Transmitted Diseases; Lentivirus Infections; Retroviridae Infections; Immunologic Deficiency Syndromes; Immune System Diseases; Disease Attributes; HIV Infections; Infections; Communicable Diseases; Organic Chemicals; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Purines; Organophosphorus Compounds; Organophosphonates; Adenine; Tenofovir; efavirenz; bictegravir, emtricitabine, tenofovir alafenamide, drug combination
• Other Study ID Numbers: Gilead ISR-CN-18-10596

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: Yes